论文部分内容阅读
目的:对消化性溃疡患者分别行奥美拉唑以及泮托拉唑治疗,观察资料效果。方法:择取本院于2015年2月-2015年11月期间收治的消化性溃疡患者82例,按照数字抽签法将患者分为奥美拉唑组与泮托拉唑组,每组各41例。对奥美拉唑组患者行奥美拉唑治疗,对泮托拉唑组患者行泮托拉唑治疗。对比两组患者的症状缓解情况以及治疗有效率。结果:奥美拉唑组患者与泮托拉唑组患者在症状缓解情况以及治疗有效率方面的数据比对不存在统计学意义,即P>0.05。结论:在消化性溃疡治疗效果方面,奥美拉唑与泮托拉唑并无明显区别,但相对而言,泮托拉唑不会对患者的肝细胞色素酶活性造成不良影响,不会阻碍人体内其他药物的代谢,且成本相对较低,总体应用性能更为显著。
Objective: To treat patients with peptic ulcer omeprazole and pantoprazole, respectively, to observe the data effect. Methods: 82 patients with peptic ulcer admitted to our hospital from February 2015 to November 2015 were enrolled. According to the digital lottery method, the patients were divided into the omeprazole group and the pantoprazole group, each with 41 example. Omeprazole was given to patients in the omeprazole group and to pantoprazole in the pantoprazole group. Compare the two groups of patients with symptom relief and treatment efficiency. Results: There was no significant difference between the two groups in the omeprazole group and the pantoprazole group in symptom relief and treatment efficiency (P> 0.05). Conclusion: In the treatment of peptic ulcer, there is no significant difference between omeprazole and pantoprazole, but in contrast, pantoprazole does not have adverse effects on the activity of hepatocytes in patients with enzymes, will not Hinder the metabolism of other drugs in the human body, and the cost is relatively low, the overall application performance is more significant.